News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Hidehito Horinouchi: Impact of Durvalumab on corticosteroid therapy for pneumonitis after chemoradiotherapy
Photo taken from Hidehito Horinouchi/X
Aug 13, 2024, 20:25

Hidehito Horinouchi: Impact of Durvalumab on corticosteroid therapy for pneumonitis after chemoradiotherapy

Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, shared on X:

“Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.

Saori Murata, Hidehito Horinouchi, Clinical Lung Cancer.

Representation of duration and complexity of tapering patterns.”

Hidehito Horinouchi

Source: Hidehito Horinouchi/X

Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.

Authors: Saori Murata, Hidehito Horinouchi, Momoko Morishita, Sawako Kaku, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Tairo Kashihara, Kae Okuma, Masahiko Kusumoto, and Yuichiro Ohe.

Hidehito Horinouchi

cancer Clinical Lung Cancer Corticosteroid Therapy Durvalumab Hidehito Horinouchi Kae Okuma Masahiko Kusumoto Momoko Morishita Noboru Yamamoto OncoDaily Oncology pneumonitis Saori Murata Sawako Kaku Tairo Kashihara Tatsuya Yoshida Yasushi Goto Yuichiro Ohe Yuki Shinno Yusuke Okuma
Special Coverage
Blog
Apr 18, 2025, 14:29
Antonio Giordano: Rep. Jesse Topper visited Sbarro Health Research Organization Genetic Research Laboratory
Blog
Apr 18, 2025, 14:07
Humaid Al-Shamsi: BCI signed an MoU with the European Institute of Oncology at Abu Dhabi Global Health Week
Blog
Apr 18, 2025, 13:54
Tanja Obradovic: Novel cell therapy is entering clinical development space
Drugs
Apr 18, 2025, 13:39
Amol Akhade: First-line treatment options for NSCLC with uncommon EGFR mutations
Blog
Apr 18, 2025, 13:07
Tanja Obradovic: Even rougher times ahead for Biotech?
Blog
Apr 18, 2025, 12:54
Adam Fein: New on Drug Channels - who really controls specialty drug dispensing?
Societies
Apr 18, 2025, 12:24
Giving Week 2025: There’s still time to activate or renew your ACS CAN membership
Positive
Apr 18, 2025, 12:14
2025 ASCO Annual Meeting Merit Award and Special Merit Award recipients
Insight
Apr 18, 2025, 11:51
Applications for 2025 Home Away From Home program are now open - Foundation S
Insight
Apr 18, 2025, 11:31
New Whitepaper Explores Cardiovascular Risks of ADT in Prostate Cancer - International Cardio-Oncology Society
Blog
Apr 18, 2025, 11:18
TLC Conference Thanks its Incredible Faculty for Making Texas Lung 25 a Success
Blog
Apr 18, 2025, 11:12
Donde Quiero Estar Foundation highlights the real barriers people with cancer face in Argentina - UICC